Alx oncology to present at 39th annual j.p. morgan healthcare conference

Burlingame, calif., jan. 05, 2021 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo) a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced that jaume pons, ph.d., founder, president and chief executive officer, will present a company overview at the 39th annual j.p. morgan healthcare conference on tuesday, january 12 at 10:50 am et.
ALXO Ratings Summary
ALXO Quant Ranking